Posted by Michael Wonder on 21 Jun 2022
Paratek Pharmaceuticals’ Nuzyra receives FDA fast track designation for the treatment of pulmonary non-tuberculous mycobacterial disease caused by mycobacterium avium complex and mycobacterium abscessus
21 June 2022 - Phase 2b study in MAB pulmonary infections on-going and enrolling as planned.
Paratek Pharmaceuticals today announced the U.S. FDA has granted fast track designation for the oral and IV formulations of the company’s novel, broad spectrum antibiotic Nuzyra (omadacycline) for the treatment of pulmonary non-tuberculous mycobacterial disease caused by both Mycobacterium avium complex and Mycobacterium abscessus.
